# The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases

> **NCT04397107** · NA · COMPLETED · sponsor: **The First Hospital of Jilin University** · enrollment: 46 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT04397107
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-15
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04397107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04397107, "The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04397107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*